Patents for A61P 35 - Antineoplastic agents (221,099)
05/2006
05/11/2006WO2002094997A3 Transcriptional regulation of target genes
05/11/2006WO2002055100A9 Method and composition for inhibition of tumor growth and enhancing an immune response
05/11/2006US20060101530 Rors as modifiers of the p21 pathway and methods of use
05/11/2006US20060100431 Biologically active compounds
05/11/2006US20060100285 N-hydroxy-4-[2-(4-trifluoromethyl-phenyl)-acetylamino]-benzamide for example; treating infammatory, autoimmune diseases, tumors, and neurodegenerative diseases
05/11/2006US20060100280 Cell growth regulator
05/11/2006US20060100261 Furan or thiopene derivative and medicinal use thereof
05/11/2006US20060100246 Synthesis of I kappa B kinase beta inhibitors that are 2-amino-4,6-disubstituted nicotinic acid ester analogs, by reacting an aryl ketone, an aldehyde and a cyanoacetate with an ammonium salt
05/11/2006US20060100240 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
05/11/2006US20060100238 4',7-Dihydroxyisoflavanone (phenyl)hydrazone; 4,7-Dihydroxyisoflavanone(4,7-dihydroxyisoflavanone)hydrazone; anticarcinogenic and antiinflammatory agents; cyclooxygenase inhibitor
05/11/2006US20060100233 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
05/11/2006US20060100227 Pyrimidine derivaties
05/11/2006US20060100211 2-(3,4-dichlorophenylamino)-4-thiocyanato-5-nitro-pyrimidine; 2-chloro-4-(2-acetylamino-ethylamino)-5-trifluoromethyl-pyrimidine; lung cancer
05/11/2006US20060100202 Novel compounds
05/11/2006US20060100199 Novel condensed imidazole derivatives
05/11/2006US20060100166 Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
05/11/2006US20060100150 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
05/11/2006US20060100140 Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
05/11/2006US20060099658 PCA3, PCA3 genes, and methods of use
05/11/2006US20060099652 IL 13 receptor alpha 2 antibody and methods of use
05/11/2006US20060099635 Anti-GL50 antibodies
05/11/2006US20060099265 Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer
05/11/2006US20060099224 Methods and compositions concerning poxviruses and cancer
05/11/2006US20060099219 Mutated hpv-16e7 polypeptide, pharmaceutical composition comprising it and its preparation process
05/11/2006US20060099218 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity
05/11/2006US20060099209 prostate and breast carcinoma; used for diagnosis to identify individuals with the high probability of having a malignant disease
05/11/2006US20060099202 Immunoglobulin construct containing tumor- specific p53bp2 sequenes for eliciting an anti-tumor response
05/11/2006US20060099189 Anti-cancer virus desensitization method
05/11/2006US20060099188 Tumor-specific promoter
05/11/2006US20060099178 Novel use of adenoviruses and nucleic acids coding therefor
05/11/2006US20060099174 Interferon-alpha induced genes
05/11/2006US20060099150 Compositions and methods for the transport of biologically active agents across cellular barriers
05/11/2006US20060099143 Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis
05/11/2006DE3571648C5 Monoklonale Antikörper gegen menschlichen Brustkrebs, ihre Produktion und Verwendung, Hybridomen zu ihrer Herstellung und Herstellung dieser Hybridomen. Monoclonal antibodies against human breast cancer, their production and use, hybridomas for their preparation and production of these hybridomas.
05/11/2006DE102004054216A1 Substituierte 4-Amino-pyridopyrimidinone Substituted 4-amino-pyridopyrimidinone
05/11/2006DE102004054215A1 Pyridopyrimidinonderivate Pyridopyrimidinonderivate
05/11/2006CA2588278A1 Anthranilamide pyridinureas as vascular endothelial growth factor (vegf)receptor kinase inhibitors
05/11/2006CA2587489A1 Mediators of hedgehog signaling pathways, compositions and uses related thereto
05/11/2006CA2586602A1 Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives
05/11/2006CA2586259A1 Novel fused imidazole derivative
05/11/2006CA2586177A1 Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
05/11/2006CA2586174A1 Methods of preparing indazole compounds
05/11/2006CA2586033A1 The use of a protease or a protease inhibitor for the manufacture of medicaments
05/11/2006CA2585934A1 Novel pyrazolopyridine urea kinase inhibitors
05/11/2006CA2585840A1 Use of an mtor inhibitor in treatment of uterine leiomyoma
05/11/2006CA2585754A1 Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostics and therapy
05/11/2006CA2584681A1 Pearmease and suicide genes for antitumoral or antiviral treatment
05/11/2006CA2583570A1 Combination comprising zd6474 and an antiandrogen
05/10/2006EP1655605A2 Treatment and diagnosis of cancer
05/10/2006EP1655382A2 Colon specific gene and protein
05/10/2006EP1655372A2 Production of polyketides and other natural products
05/10/2006EP1655369A1 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
05/10/2006EP1655305A2 Therapeutic anti-cytomegalovirus compounds
05/10/2006EP1655289A1 Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives
05/10/2006EP1655284A1 2-Phenylsulfopyrroles
05/10/2006EP1655039A2 Immunoliposomes that optimize internalization into target cells
05/10/2006EP1655038A1 Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same
05/10/2006EP1655036A1 Method for treating oncological diseases
05/10/2006EP1654380A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
05/10/2006EP1654377A2 Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
05/10/2006EP1654353A2 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
05/10/2006EP1654349A2 Sulfs as modifiers of the beta catenin pathway and methods of use
05/10/2006EP1654287A2 Cd20-binding polypeptide compositions
05/10/2006EP1654257A1 Aminopyrones and their use as atm inhibitors
05/10/2006EP1654245A1 Benzofuran derivatives useful for treating hyper-proliferative disorders
05/10/2006EP1654236A1 Naphthylene derivatives as cytochrome p450 inhibitors
05/10/2006EP1654220A1 Compounds for modulating cell proliferation
05/10/2006EP1653992A1 Use of a vegf antagonist in combination with radiation therapy
05/10/2006EP1653990A1 Use of polypeptides of the cupredoxin family in cancer therapy
05/10/2006EP1653975A1 Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
05/10/2006EP1653973A1 Combinations comprising staurosporines
05/10/2006EP1653967A2 Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
05/10/2006EP1653964A1 Cancer combination therapy comprising azd2171 and zd1839
05/10/2006EP1653961A1 Inhibitors of akt activity
05/10/2006EP1653957A1 Piperidine compounds useful as malonyl-coa decarboxylase inhibitors
05/10/2006EP1653951A1 Benzimidazole derivatives as raf kinase inhibitors
05/10/2006EP1653946A2 Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
05/10/2006EP1653944A1 Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors
05/10/2006EP1653943A2 Compounds and methods for inducing apoptosis in cancer cells
05/10/2006EP1653940A1 Therapeutic combination of a cox-2 inhibitor and an aromatase inhibitor
05/10/2006EP1653912A2 Vaccine immunotherapy for immune suppressed patients
05/10/2006EP1495006A4 Inhibitors of glycinamide ribonucleotide transformylase
05/10/2006EP1483374B1 Use of l-alpha-lysophosphatidycholine to obtain the differentiation of monocytes in mature dendritric cells in vitro
05/10/2006EP1418911B1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
05/10/2006EP1379694B1 Methods and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
05/10/2006EP1370553B1 Rho-kinase inhibitors
05/10/2006EP1294874B1 Cd154 variants and uses thereof
05/10/2006EP1290012B1 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
05/10/2006EP1282641B1 Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferation of cancer cell using the expression vector
05/10/2006EP1212296B9 Phosphate mimics and methods of treatment using phosphatase inhibitors
05/10/2006EP1210355B1 Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
05/10/2006EP1154798B1 Molecules for the treatment and diagnosis of tumors
05/10/2006EP1150696B1 Genetically engineered herpes virus for the treatment of tumours
05/10/2006EP1145001B1 (in vitro) model for gastrointestinal inflammation
05/10/2006EP1140786B9 Reductive alkylation of secondary amines with hydrosilane
05/10/2006EP1104403B1 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors
05/10/2006EP1003548B1 Device for inducing a ctl response
05/10/2006EP0873049B1 Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
05/10/2006CN1771325A Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs
05/10/2006CN1771263A Modified acacia and use thereof